The study also found that FK506 (tacrolimus) could inhibit IL-8 production, indicating its potential as a combination therapy with anti-RANKL antibody to improve treatment outcomes in RA by reducing osteoclastogenesis-promoting IL-8 levels [197]. The gene discussed is CXCL8; the disease is rheumatoid arthritis.